Enanta Pharmaceuticals 有望于2026年下半年提交EPS-3903新药临床试验申请并选定Mrgprx2候选药物

美股速递
May 12

Enanta Pharmaceuticals Inc. 宣布,公司正按计划推进,目标在2026年下半年提交其候选药物EPS-3903的新药临床试验申请,并完成针对Mrgprx2靶点的候选药物的选定工作。这两项进展标志着该公司在相关治疗领域的研发管线取得了重要阶段性成果。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10